Physician profile
Richard E Hoyt
NPI 1609064617
$2,920.71
in general payments reported to CMS, 2019-2025
14 companies · $573 in 2025
The $573 reported for 2025 was more than what 81% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $230 · 2021: $84.61 · 2022: $200 · 2023: $263 · 2024: $1,375 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,370 · Travel and Lodging: $841.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,370.07 |
| Travel and Lodging | $840.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $1,020.97 | 2024 | Iovera |
| Abbvie INC. | $753.39 | 2021-2025 | |
| Allergan, INC. | $326.42 | 2019-2022 | |
| Merz Pharmaceuticals, LLC | $224.17 | 2021-2025 | Xeomin |
| Boston Scientific Corporation | $145.54 | 2025 | Intracept |
| Lilly USA, LLC | $110.11 | 2019-2024 | Emgality, Reyvow |
| Lundbeck LLC | $82.62 | 2024-2025 | Vyepti |
| Merz North America, INC. | $71.78 | 2020 | |
| Amgen INC. | $68.70 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $55.75 | 2024-2025 | Ajovy |
| Bioventus LLC | $18.17 | 2024 | Durolane |
| Biohaven Pharmaceutical Holding Company LTD. | $15.85 | 2022 | |
| Averitas Pharma INC. | $15.33 | 2025 | Qutenza |
| Scilex Pharmaceuticals INC. | $11.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Hoyt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.